Business Context and Reporting Period
This Form 8-K Current Report was filed by EyeGate Pharmaceuticals, Inc. (not Kiora Pharmaceuticals) on March 30, 2021, with the earliest event reported on that date. The filing addresses significant changes to the Company's Board of Directors effective April 1, 2021.
Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Board Resignations: Dr. Morton Goldberg, Thomas Hancock, and Bernard Malfroy-Camine resigned from the Board of Directors and all committees, effective April 1, 2021. The Company stated these resignations were not due to any disagreement with the Company.
- Board Appointments: Kenneth Gayron and Aron Shapiro were appointed to the Board to fill the vacancies, effective April 1, 2021. Both are classified as independent directors under Nasdaq rules.
- Committee Assignments:
- Kenneth Gayron: Appointed Chair of the Audit Committee, Audit Committee Financial Expert, and member of the Compensation Committee.
- Aron Shapiro: Appointed member of the Compensation Committee and the Nominating and Corporate Governance Committee.
- Compensation: New directors will receive compensation consistent with the Company's existing non-employee director structure as described in the 2020 Proxy Statement.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding business operations. It includes a standard disclosure under Item 7.01 (Regulation FD) referencing a press release issued on April 1, 2021, which is incorporated by reference but not deemed "filed" for liability purposes under Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the specific reasons for the departure of three directors, despite the Company's statement that no disagreements occurred.
- Review the professional backgrounds of new directors Kenneth Gayron (former CFO of Avid Technology and Osmotica) and Aron Shapiro (Senior VP at Ora, Inc.) to assess their strategic fit for a pharmaceutical company.
- Confirm the composition of the Audit Committee and the designation of the Audit Committee Financial Expert following the appointment of Mr. Gayron.
- Check the Company's 2020 Proxy Statement for details on the director compensation package applicable to the new appointees.